Ftse Mib
33.242,20
0,04%
DAX
19.093,18
0,48%
S&P 500
5.917,11
0,00%
NASDAQ
18.966,14
0,00%
Bitcoin
97.606,43
3,44%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Europa EU Argen X SE (ARGX) Argen X SE (ARGX) Notizie

Argen X SE

ARGX
551,40
-2,20 (-0,40%)
Ultimo aggiornamento: 14:40:41
Dati in Delay di 15 minuti
Borsa: Euronext
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
20/11/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod SC in..
11/11/202413:30GLOBEargenx and Zai Lab Announce Approval of VYVGART Hytrulo for..
05/11/202407:00GLOBEargenx to Participate at Upcoming Investor Conferences
31/10/202407:00GLOBEargenx Reports Third Quarter 2024 Financial Results and..
24/10/202407:00GLOBEargenx to Report Third Quarter 2024 Financial Results and..
15/10/202407:00GLOBEargenx Highlights Data Showing Patient Impact Across..
19/9/202407:00GLOBEargenx Announces Publication in The Lancet Neurology of..
28/8/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
25/7/202407:00GLOBEargenx Reports Half Year 2024 Financial Results and Provides..
18/7/202407:00GLOBEargenx to Report Half Year 2024 Financial Results and Second..
16/7/202406:30GLOBEargenx and Zai Lab Announce Approval of Efgartigimod Alfa..
25/6/202422:30GLOBEargenx Highlights Breadth of Autoimmune Pipeline with New..
21/6/202422:50GLOBEargenx Announces FDA Approval of VYVGART Hytrulo for Chronic..
17/6/202407:00GLOBEargenx to unveil its ‘Vision 2030: Taking Breakthrough..
04/6/202407:00GLOBEargenx to Present at Goldman Sachs 45th Annual Global..
09/5/202407:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
07/5/202423:30GLOBEargenx announces results of Annual General Meeting of..
07/5/202407:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/5/202407:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/4/202407:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/3/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/3/202421:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202407:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07/3/202422:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/2/202407:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/2/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
22/2/202407:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/2/202407:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/1/202407:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/1/202407:00GLOBEargenx Highlights 2024 Strategic Priorities
02/1/202407:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202307:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202307:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
Apertura: 550,60 Min: 548,60 Max: 553,00
Chiusura: 553,60

La tua Cronologia

EU
ARGX
Argen X
BIT
UCG
Unicredit
USOTC
AUCTF
Aucnet (PK)
USOTC
ADSV
Allied Security Innovati... (CE)
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network